SDGRHealthcare · Health Information ServicesThe 7 Wall Street analysts covering Schrödinger, Inc. hold a median 12-month price target of $20 — -22.8% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 55 of 100 as at 12 Oct 2026 — in the upper half.
Consensus tells you what everyone already believes. The model scores Schrödinger, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Growth (88): Sales and profits are climbing, and climbing faster than before.
Value (29): The shares cost a lot relative to the profits and assets behind them.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on SDGR, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits −22.8% from it.
Of the 20 most recent actions, 2 moved their price target up and 1 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 12 Oct 2026 | BMO Capital | Maintains | Outperform | $24 → $30 |
| 14 Aug 2026 | UBS | Assumes | Neutral | $13 → $19 |
| 14 May 2026 | Morgan Stanley | Maintains | Equal-Weight | $19 → $17 |
| 14 May 2026 | Morgan Stanley | Maintains | Equal-Weight | — |
| 8 Apr 2026 | Keybanc | Maintains | Overweight | — |
| 17 Mar 2026 | UBS | Maintains | Neutral | — |
| 8 Jan 2026 | Keybanc | Maintains | Overweight | — |
| 8 Jan 2026 | TD Cowen | Maintains | Buy | — |
| 7 Jan 2026 | UBS | Initiates | Neutral | — |
| 15 Dec 2025 | B of A Securities | Upgrade | Buy | — |
| 8 Oct 2025 | Keybanc | Maintains | Overweight | — |
| 30 Sept 2025 | Goldman Sachs | Initiates | Neutral | — |
| 18 Aug 2025 | Morgan Stanley | Maintains | Equal-Weight | — |
| 15 Aug 2025 | Citigroup | Downgrade | Neutral | — |
| 14 Aug 2025 | Barclays | Initiates | Overweight | — |
| 14 July 2025 | Keybanc | Maintains | Overweight | — |
| 16 Apr 2025 | Keybanc | Maintains | Overweight | — |
| 27 Feb 2025 | Piper Sandler | Maintains | Overweight | — |
| 24 Jan 2025 | Keybanc | Maintains | Overweight | — |
| 13 Nov 2024 | BMO Capital | Maintains | Outperform | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. SDGR appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 13 Oct 2026, Schrödinger, Inc. returned +31.4% against +18.6% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 17% of US stocks
Cheaper than 18% of US stocks
Cheaper than 17% of US stocks
Cheaper than 86% of US stocks
Higher than 45% of US stocks
Higher than 45% of US stocks
Higher than 68% of US stocks
Higher than 15% of US stocks
Higher than 15% of US stocks
Higher than 33% of US stocks
Higher than 23% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Schrödinger, Inc. has a market value of $2.0B and an enterprise value of $1.7B.
Revenue in the twelve months to 30 June 2026: $259.0M. The latest quarter grew 7.5% year on year.
Net income over the same four quarters: −$54.3M, a −21.0% net margin.
Free cash flow in the twelve months to 30 June 2026: −$130.3M.
Trailing P/E: 44.4×; forward P/E: −19.1× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Schrödinger, Inc. employs 850 people — $305K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Schrödinger, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Schrödinger (SDGR) shares rose 7.6% in the latest session on above-average trading volume. The excerpt says recent earnings estimate revisions suggest potential for further strength.
Why it matters — SDGR watchers may note the share-price move and the reported trend in earnings estimate revisions.
Meta rose 11% on Monday on early traction for its Muse AI agent, while Interactive Brokers chief strategist Steve Sosnick said his customers were selling into the move, with Meta the most-sold stock on the platform. Ross Gerber presented a bear case on social media and a bull case on Nvidia.
Why it matters — The item concerns other companies and does not contain Schrödinger-specific news, so it offers no direct material signal for SDGR watchers.
Schrödinger, Inc. has made significant strategic changes, including pipeline cuts and a pivot away from solo clinical development. The company's financial position improved with the Ajax sale, a stronger balance sheet, a positive net income in Q2 2026 aided by a $48.9M gain, and cash reserves rising to $418.8M, despite software growth deceleration and pipeline setbacks.
Why it matters — SDGR watchers would care because the company's business model is shifting from solo drug development toward company creation, with improved financials from the Ajax sale that reshape how its performance should be evaluated.
On September 13, 2026, Schrödinger, Inc. granted restricted stock units covering 2,243 shares of common stock to three newly hired employees. The grants were made under the company's 2021 Inducement Equity Incentive Plan and were approved by the compensation committee of the board of directors pursuant to a delegation by the board.
Why it matters — SDGR watchers would note this as a routine disclosure of equity-based compensation used to attract incoming employees under the company's inducement incentive plan.
Schrödinger, Inc. presented at the Morgan Stanley 24th Annual Global Healthcare Conference, and the transcript of its presentation was published. The item reports the company's participation at the conference without providing any commentary on the presentation itself.
Why it matters — SDGR watchers would care because the conference presentation and its transcript offer visibility into how the company is communicating with the investment community at a major healthcare conference.
The 7 Wall Street analysts covering Schrödinger, Inc. have a median 12-month price target of $20, with estimates ranging from $17 to $30. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 7 analysts covering Schrödinger, Inc., 5 rate it a Buy, 2 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Schrödinger, Inc. 55 out of 100 across roughly 4,600 US stocks as at 12 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 12 Oct 2026, Schrödinger, Inc. ranks 55 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Growth (88 of 100).
No one can know that. What the data says: the median 12-month target from 7 analysts implies -22.8% from the last close, and Ticker Nerd's factor model ranks Schrödinger, Inc. 55 out of 100 as at 12 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Schrödinger, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for SDGR are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $17 to $30 over the next 12 months.
Schrödinger, Inc. returned +31.4% over the 12 months to 13 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
Schrödinger, Inc. is a life sciences software and biotechnology company that develops a physics-based computational platform for molecular discovery.
The most recent item we track (Zacks Investment Research, 6 Oct 2026): "Schrodinger (SDGR) Surges 7.6%: Is This an Indication of Further Gains?". Schrödinger (SDGR) shares rose 7.6% in the latest session on above-average trading volume. The excerpt says recent earnings estimate revisions suggest potential for further strength.
Schrödinger, Inc. is a life sciences software and biotechnology company that develops a physics-based computational platform for molecular discovery. The company provides software tools used to model and simulate chemical and biological systems, helping researchers identify and optimize novel molecules for drug discovery and materials science. Its platform is used across the pharmaceutical, biotechnology, materials, and industrial research sectors, supporting workflows such as molecular design, simulation, and collaboration. Schrödinger also operates a drug discovery segment that applies its technology to proprietary and partnered research programs. Headquartered in New York and founded in 1990, Schrödinger plays a specialized role in the market as a provider of advanced computational chemistry solutions for scientific innovation.
CEO Dr. Ramy Farid Ph.D. · 850 employees · United States · https://www.schrodinger.com
